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Abstract
Studies have characterized absolute levels of multiple inflammatory agents as significant risk 
factors for poor outcomes after traumatic brain injury (TBI). However, inflammatory marker 
concentrations are highly inter-related, and production of one may result in the production or 
regulation of another. Therefore, a more comprehensive characterization of the inflammatory 
response post-TBI should consider relative levels of markers in the inflammatory pathway. We 
used principal component analysis (PCA) as a dimension-reduction technique to characterize the 
sets of markers that contribute independently to variability in cerebrospinal (CSF) inflammatory 
profiles after TBI. Using PCA results, we defined groups (or clusters) of individuals (n=111) with 
similar patterns of acute CSF inflammation that were then evaluated in the context of outcome and 
other relevant CSF and serum biomarkers collected days 0-3 and 4-5 post-injury. We identified 
four significant principal components (PC1-PC4) for CSF inflammation from days 0-3, and PC1 
accounted for the greatest (31%) percentage of variance. PC1 was characterized by relatively 
higher CSF sICAM-1, sFAS, IL-10, IL-6, sVCAM-1, IL-5, and IL-8 levels. Cluster analysis then 
defined two distinct clusters, such that individuals in cluster 1 had highly positive PC1 scores and 
relatively higher levels of CSF cortisol, progesterone, estradiol, testosterone, brain derived 
neurotrophic factor (BDNF), and S100b; this group also had higher serum cortisol and lower 
serum BDNF. Multinomial logistic regression analyses showed that individuals in cluster 1 had a 
10.9 times increased likelihood of GOS scores of 2/3 versus 4/5 at 6 months compared to cluster 2, 
after controlling for covariates. Cluster group did not discriminate between mortality compared to 
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GOS scores of 4/5 after controlling for age and other covariates. Cluster groupings also did not 
discriminate mortality or 12 month outcomes in multivariate models. PCA and cluster analysis 
establish that a subset of CSF inflammatory markers measured in days 0-3 post-TBI may 
distinguish individuals with poor 6-month outcome, and future studies should prospectively 
validate these findings. PCA of inflammatory mediators after TBI could aid in prognostication and 
in identifying patient subgroups for therapeutic interventions.
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1. Introduction
Traumatic Brain Injury (TBI) occurs in 2.5 million Americans yearly, resulting in 50,000 
deaths annually as a direct result of injury (CDC, 2010). There have been numerous 
experimental and clinical studies of secondary injury cascades. Further, TBI has been 
characterized by: direct disruption of brain tissue, excitotoxicity, hormone pathophysiology, 
oxidative stress, as well as an aseptic central and peripheral inflammatory response. TBI is 
heterogeneous with respect to age, sex, initial severity, imaging findings, mechanism of 
injury, and development of infections and other complications. Clinical trials have not been 
successful to date in identifying any definitive neuroprotective treatment (Maas et al., 2010). 
This failure could be due, in part, to a lack of reconciliation between the nuances associated 
with human patient heterogeneity that occurs with TBI and the clean experimental modeling 
conditions of preclinical research. The ability to utilize an adaptive trial design to triage and 
stratify subgroups based on this heterogeneity prior to enrollment and randomization could 
enhance the identification of clinical intervention targets for future therapies that are 
efficacious for relevant subsets of the population. However, it is possible that the search for 
biomarkers in the field of TBI has largely failed because a majority of efforts have focused 
on identifying a single “magic bullet” that hits a singular therapeutic target in a relatively 
homogeneous population, which likely oversimplifies the pathophysiology and the approach 
to clinical trial investigations for individuals with TBI.
Post-traumatic inflammation is a complex component of the secondary injury cascade that 
has been well-documented in both humans and experimental models (Jeong et al., 2013; 
Lucas et al., 2006; Woodcock and Morganti-Kossmann, 2013). Studies have characterized 
certain candidate cytokines, chemokines, cell-surface markers, and microglia as elevated 
early after injury compared to uninjured controls (Woodcock and Morganti-Kossmann, 
2013). Contemporary concepts contend that controlled inflammation is necessary to clear 
debris and damaged cells early following TBI, while sustained elevations of inflammatory 
markers, such as IL-1β, TNFα, and IL-6, are deleterious if not physiologically regulated and 
can lead to an increased risk of depression (Juengst et al., 2014), epilepsy (Diamond et al., 
2014), cognitive deficits (Clausen et al., 2009, 2011) and poor global outcomes (Kumar et 
al., 2014).
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Work using lipopolysaccharide (LPS)-challenge as an experimental model of inflammation 
suggests that cytokines are highly correlated with one another, and the production of one 
biomarker directly or indirectly impacts production and release of others (Hang et al., 2004). 
Despite this consideration, human studies to date have strongly focused on absolute, not 
relative, levels of CSF and serum inflammatory biomarkers produced after TBI. That is, 
there exists little knowledge of which markers account for similar patterns of variance 
among patients or which inflammatory agents may “track together” after TBI. It could be of 
considerable clinical significance to not only know which markers are elevated relative to 
controls, but also which sets of markers share some discriminatory capacity among patient 
outcomes early after injury. Such information may be useful to inform prognosis and guide 
therapy. For example, a given biomarker may be elevated 10-fold in patients vs. controls; 
however, it may have little variability among patients, making it less useful as a prognostic 
marker compared to other markers that may have a wide range of concentrations in the 
patient population.
Taking a data-driven approach to discriminating patient subgroups, we evaluated relative 
CSF inflammatory levels in the first week after injury to identify which sets of markers 
account for the greatest variability among patients. To this end, we used dimension 
reduction methods, including principal component analysis (PCA) and cluster analysis, to 
identify independent subgroups of patients with similar inflammatory responses following 
TBI, without incorporating any prior knowledge of post-TBI immunity into the modeling 
strategy and independent of any known relationships to outcome or recovery after injury. 
PCA is a statistical technique that has been applied into a number of disciplines, including 
biology, medicine, and the social sciences. In the healthcare field, PCA has been applied to a 
variety of diseases including cardiovascular disease (Nettleton et al., 2007), autism 
(Tadevosyan-Leyfer et al., 2003), depression (Hamilton, 1967), and cancer (Machado et al., 
2005). In TBI, the data are limited; one small study of 12 individuals used microdialysis to 
examine the inflammatory profiles using PCA methodology (Helmy et al., 2012).
In this study, 1) we applied PCA to CSF inflammatory marker data derived from our large 
cohort with severe TBI to identify parameter combinations (known as principal components) 
that account for the variability across individuals, 2) we used these principal components to 
identify meaningful clusters of individuals in our study population, and 3) we assessed the 
association between cluster group membership and relevant demographic and clinical 
variables, previously measured biomarkers, and outcomes in the first year after TBI.
Using relative levels of inflammatory agents to characterize sets of markers that account for 
the greatest variation among individuals with TBI could have significant implications for 1) 
prognostication, 2) identifying individuals who may be good candidates for therapeutic 
intervention, 3) detecting which sets of markers have strong discriminatory potential and 
could represent targets for interventions, and 4) delineating potential treatment windows for 
inflammation-related interventions in a clinical trial. Overall, this data-driven approach 
provides a novel assessment of the potential of patterns among TBI-associated inflammatory 
biomarkers to predict long-term outcomes after TBI.
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2. Materials and Methods
2.1. Study Protocol
This prospective, observational cohort study was approved by the University of Pittsburgh 
Institutional Review Board. We enrolled 114 adults with severe closed-head TBI at our level 
1 trauma center. Patients were eligible if they were between ages 16-75 years, had a severe 
TBI based on an admission Glasgow coma scale (GCS) score ≤8 with positive findings on 
head CT, required an extraventricular drainage catheter (EVD) for intracranial pressure 
(ICP) monitoring and management, and had at least two CSF and/or serum samples 
collected during the first week post-injury available for analysis.
Individuals were excluded from our analysis if they exhibited any of the following: a 
penetrating head injury, documented prolonged cardiac or respiratory arrest at injury (>30 
minutes occurring prior to admission), or evidence of brain death within the first three days 
after injury; an Abbreviated Injury Scale (AIS) score of 5 in any region other than the head/
neck; a previous history of pituitary or hypothalamic tumor, history of breast cancer 
requiring chemotherapy treatment/tamoxifen, history of prostate cancer requiring 
orchiectomy or LH suppression agents, or untreated thyroid disease.
Individuals with TBI received care consistentwith The Guidelines for the Management of 
Severe Head Injury (Brain Trauma Foundation et al., 2007). This care included initial EVD 
placement, central venous catheter and arterial catheter placement, and surgical intervention 
for decompression of mass lesions when clinically indicated. Intracranial pressure was 
treated in a stepwise fashion to maintain pressure within normal parameters (<20 mmHg), 
and cerebral perfusion pressure (CPP) was maintained at >60mmHg. Also, there were a total 
of n=6 participants enrolled in a randomized controlled trial evaluating maintenance of 
moderate hypothermia (temperature 32.5-33.5°C) after severe TBI. All the patients not 
enrolled in the trial were treated to maintain a normothermic state.
2.2. Sample Collection and Processing
CSF samples (n=567) were collected passively via EVD placed for clinical care, and 
samples were collected up to twice daily for up to 5 days after injury. The samples were 
collected at 7 AM or 7 PM, whenever possible, and were stored at 4°C until processing. For 
some individuals, clinical care, medical stability, minimal CSF output, or removal from the 
intensive care unit (ICU) precluded the acquisition of CSF samples at certain time points. 
Serum samples (n=610) were also collected on a subset of individuals (n=84). All CSF and 
serum samples were centrifuged, aliquoted, and stored at -80°C until batch analysis.
CSF inflammatory markers were measured using a Luminex™ bead array assay (Millipore, 
Billerica, Massachusetts). Multiplex bead array assays use a microsphere tagged with 
multiple fluorescent-labelled markers. A fluorescence detection laser optic system was used 
to analyze simultaneous individual protein binding. Single samples were used for analysis 
for each Luminex assay. The markers measured in CSF included the following cytokines 
and cell-surface markers: interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, and 
tumor necrosis factor alpha (TNF-α), soluble vascular adhesion molecule-1 (sVCAM-1), 
soluble intracellular adhesion molecule-1 (sICAM-1), and soluble Fas (sFAS). The 
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minimum detectable limit and coefficient of variance for each marker have been previously 
reported in detail by our group (Santarsieri et al., 2015).
In addition to inflammatory markers, a battery of steroid hormones, brain-derived 
neurotrophic factor (BDNF), and S100b were also assessed as TBI-relevant biomarkers in 
CSF and serum. These markers have been previously measured and reported on 
independently in prior studies (Failla et al., 2015; Goyal et al., 2013; Santarsieri et al., 2015; 
Wagner et al., 2011). CSF and serum cortisol, as well as serum testosterone (T), estradiol 
(E2), and progesterone, were measured using radioimmunoassay with the Coat-A-Count ® 
In-vitro Diagnostic Kit (Siemens Healthcare Diagnostics Inc., Los Angeles, CA). Estradiol 
and testosterone were measured using high sensitivity enzyme immunoassay (EIA) kits 
(Salimetrics, LLC. State College, PA). A ratio was also created with E2 over T, as 
previously reported, to represent a measure of aromatization (Garringer et al., 2013). CSF 
and serum BDNF levels were measured using an enzyme-linked immunosorbent assay 
(ELISA) kit (RayBiotech, Norcross, GA). Similarly, CSF and Serum S100b levels were also 
measured using ELISA kits (International Point of Care Inc., Toronto, Ontario, Canada).
2.3. Demographic and Clinical Variables
Relevant demographic and clinical variables were gathered through a combination of 
personal interview and medical record abstraction. The variables collected for this study 
include: age, sex, body mass index (BMI), GCS score, Injury Severity Scale (ISS) score, 
mechanism of injury, initial computed tomography (CT) imaging findings, hospital length of 
stay, and the development of sepsis and pneumonia during hospital stay. The GCS, a 
ubiquitously used measure of neurological injury severity based on verbal, motor, and eye 
responses, was assessed serially by trained clinical ICU staff. The best GCS score in the first 
24 hours was used in this study. Trauma research staff abstracted ISS scores from the top 
three most injured body regions detailed from regional AIS score assignments, which is a 
commonly used anatomical trauma scoring scale that quantifies overall severity of injury 
across multiple anatomical regions (Baker et al., 1974). Pneumonia and sepsis status was 
abstracted from our local hospital trauma registry.
2.4. Six and 12 Month Outcome Assessment
Individuals with acute biomarker samples were followed-up at six (85.6% follow-up rate) 
and 12 months (80.2% follow-up rate) for the assessment of global recovery using the 
Glasgow Outcome Scale (GOS). The GOS is a global measure of neurological recovery 
ranging from 1-5, with scores corresponding to: 1) dead, 2) vegetative state, 3) severe 
disability, 4) moderate disability, and 5) good recovery (Jennett and Bond, 1975). 
Participant's GOS scores were divided into three categories: 1) dead (GOS=1); 2) severe 
disability (GOS=2/3); or 3) favorable outcomes (GOS=4/5).
In addition to GOS, a post-hoc analysis was conducted using Disability Rating Scale (DRS) 
scores at 6 and 12 months. The DRS is a scale developed to assess individuals in the 
rehabilitation phase of recovery, and includes eight items divided into four subscales: 1) 
arousal and awareness, 2) cognitive ability to handle self-care functions, 3) physical 
dependence upon others, and 4) psychosocial adaptability for work, housework, or 
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school(Rappaport et al., 1982). The scores range from 0 to 30, with lower scores indicating 
no disability and 30 indicating death. For the purposes of the post-hoc analysis among only 
survivors, DRS scores were utilized for the purpose of having an outcome scale with slightly 
more granularity among survivors than the GOS. Scores were divided into three categories, 
1) partial to no disability (DRS=0-3); 2) moderate or severe disability (DRS=4-14); 3) 
extreme severe disability, vegetative state or dead (DRS=15-29).
2.5. Statistical Analysis
All statistical analyses were performed using SAS version 9.4. Descriptive statistics, 
including medians, means, and standard error of the mean (SEM), were computed for 
continuous variables. Frequencies and percentages were determined for categorical 
variables. Non-parametric Mann Whitney U tests were conducted for continuous variables, 
and chi-square tests, or Fisher's Exact Test when appropriate, were used for categorical 
variables. All tests were two-tailed, with a significance level set at α=0.05.
For the purposes of this study, samples were divided into two time epochs after injury, days 
0-3 and days 4-5, which represent an early and late measure for biomarker levels in the first 
week following TBI. These time frames were chosen based on prior biomarker work from 
our lab showing these time points as sensitive to mortality and global outcomes (Wagner et 
al., 2015).
Average values for each biomarker were calculated within days 0-3 and days 4-5. The data 
were analyzed in three stages outlined below, which include: 1) PCA, 2) cluster analysis, 
and 3) bivariate and multivariate analyses stratified by cluster groups.
In addition, a post-hoc analysis was conducted exploring differences in levels of CSF 
inflammatory markers among individuals in the 75th percentile or above for age, compared 
to those below the 75th percentile for age.
2.5.1. Principal Component Analysis—PCA is a statistical method that identifies 
sources of variation within data and serves as a dimension-reducing procedure for a set of 
correlated continuous variables (Bryant and Yarnold, 1995; Grimm and Yarnold, 1995). 
PCA is an ideal analytical approach to use with hypothesis-generation studies, as it does not 
rely on any a priori knowledge of the relationship amongst the variables of interest. This 
data-driven technique identifies uncorrelated linear combinations of observed variables, 
called principal components, which explain the greatest degree of variance among a set of 
observed variables, within a specified study population (Suhr, 2005). The principal 
components are organized in order of descending independent contribution to discrimination 
of variance in the data (i.e. PC1>PC2, PC2>PC3, etc.). Mathematically, the principal 
components correspond to eigenvectors of a covariance matrix formed from the data, while 
the associated eigenvalues quantify components' contributions to discrimination of variance 
in the data.
The principal components can be thought of as providing a new coordinate system for the 
data, with the greatest spread of data along the first coordinate, as illustrated in the 
schematic diagram in Figure 1. For example, in a hypothetical real-world application of 
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PCA, measurements could be gathered from a cohort for Hemoglobin-A1C and capillary 
blood glucose. PCA could then yield principal components PC1 and PC2, each 
corresponding to a different linear combination of the measured quantities. Although PCA 
does not provide biological interpretations for the principal components, in this simple 
example, we can hypothesize that PC1 might represent variance associated with severity of 
diabetes, while PC2 would account for the remaining variance in the population not 
captured by PC1. With data sets of dimensions greater than two, such as our CSF 
inflammatory biomarker data, dimension reduction is obtained by identifying a subset of 
dominant principal components that account for a sufficiently large proportion of the 
variance in the data and projecting data onto this lower-dimensional subset. In such settings, 
there is rarely as clear a biological interpretation of the dominant principal components as 
there is in our hypothetical example yet, crucially, the link with variance remains.
Prior to performing PCA, days 0-3 and 4-5 averages for each CSF inflammatory marker 
were z-score standardized to account for inherent differences in absolute concentrations of 
certain markers relative to one another. The formula utilized for z-score standardization was: 
z-score= (x-μ)/σ, where x corresponds to subject mean, μ corresponds to study population 
mean, and σ corresponds to study population standard deviation.
After z-score standardization, data in days 0-3 and 4-5 were assessed independently by PCA 
using the SAS procedure PROC FACTOR, specifying “prin” as the analytic method. We 
utilized the Kaiser criterion for significant principal component inclusion, which specifies 
that only principal components that have eigenvalues greater than 1 will be retained (Kaiser, 
1960). No rotations were made on the data.
For each inflammatory marker, there was a “loading” associated with each principal 
component, which ranged from -1 to 1. The size of this loading measures how significant a 
contribution a marker makes to a principal component, while its sign determines whether a 
larger-than-average (positive) or smaller-than-average (negative) level of that marker is 
associated with positive variation in that principal component. Given these loadings, each 
subject received a “score” for each significant principal component for days 0-3 and 4-5, 
respectively (e.g. PC1 score, PC2 score, etc. for each time range). A subject's score for a 
principal component was based on that individual's particular data for the variables that load 
with that component and was computed by taking the dot product of the patient's z-score 
standardized data with the corresponding principal component. That is, if a subject had high 
levels of markers with large positive loadings for a principal component, then that individual 
would be assigned a large positive score for that component, whereas high levels of markers 
with large negative loadings would lead to a negative score, and levels of markers with 
small loadings would have little influence on the subject's score.
2.5.2. Cluster Analysis—After PCA, a non-hierarchical, k-means cluster analysis was 
run using all of the scores for significant principal components generated from PCA for days 
0-3 and 4-5, respectively. The purpose of clustering was to derive meaningful 
subpopulations of patients with TBI that had similar relationships among inflammatory 
markers that loaded(i.e. had large positive or negative loadings) for each significant 
principal component (e.g. PC1, PC2). K-means cluster analysis involves the following steps: 
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1) arbitrarily choosing k observations as seeds, 2) assigning each remaining observation to 
the seed closest to it in Euclidean distance, in order to form temporary clusters, and 3) 
repeating this process until convergence is reached and final clusters are formed (MacQueen 
et al., 1967). All clustering was performed using the SAS procedure PROC FASTCLUS. 
The cubic clustering criterion (CCC) was noted for days 0-3 and 4-5 clusters; values greater 
than 2 were considered a benchmark for good cluster grouping, while values less than 2 
were considered to be a poor cluster grouping (Sarle, 1983). If a cluster group contained 
only 1 individual, it was removed from analyses. Author expert judgment was used to 
combine certain nearby cluster groups, as appropriate.
2.5.3. Bivariate and Multivariate Analyses—The primary outcome of interest was 
GOS category (dead, GOS=1; vegetative state/severe disability, GOS=2/3; or moderate 
disability-good recovery, GOS=4/5). Relevant demographic and clinical variables were 
compared by cluster group and GOS in bivariate analyses. To control for the potential 
effects of confounders, variables significantly associated with both cluster group and GOS 
were controlled for in multivariate analyses. First, the proportional odds assumption was 
tested for the multivariate ordinal logistic regression model. Since the proportionality 
assumption was violated, a multinomial logistic regression was performed with the data. In 
addition to GOS, DRS scores were compared among survivors in a bivariate relationship to 
cluster membership. Finally, additional TBI-related serum and CSF biomarker levels 
(steroid hormones, BDNF, and S100b) were compared by cluster group in bivariate 
analyses.
3. Results
3.1. Principal Component Analysis: Days 0-3 and Days 4-5
PCA produced four significant principal components (eigenvalue>1) for days 0-3 and three 
significant principal components for days 4-5. Each principal component consists of a vector 
of coefficients weighting the contribution of each measured biomarker to that component. 
The coefficients of each biomarker in the two dominant principal components for days 0-3 
and 4-5 (specifically PC1 and PC2 for each time interval) are graphed in Figure 2a/b. The 
principal component loadings for days 0-3 and 4-5 are provided in Table 1, with bolded 
values representing inflammatory markers that loaded greater than or equal to |0.4| for a 
given principal component.
3.2. Cluster Analysis: Days 0-3 and Days 4-5
For each individual, we derived a principal component score for each significant principal 
component (i.e. PC1 score, PC2 score, etc. for days 0-3; PC1 score, PC2 score, etc. for days 
4-5). These scores were tested for significant cluster groupings among the study population 
using k-means cluster analysis. The k-means clustering algorithm works by partitioning n 
observations into k clusters, where each observation (subject) is assigned to the cluster with 
the closest mean. For days 0-3, five clusters were obtained; two of them contained only one 
individual each and were removed from the analysis. One cluster contained only four 
individuals and was therefore combined with another larger cluster that had similar (non-
significantly different) mean PC1 scores (p=0.243). These steps yielded two cluster groups 
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that were extracted and utilized for subsequent analysis: cluster 1 (n=32) and cluster 2 
(n=79). The CCC for this cluster grouping was 3.674, which values greater than two are 
indicative of good cluster groupings(Sarle, 1983). For the day 0-3 data for each individual, 
we plotted the score for PC1 against the score for PC2; Figure 3 shows these data, stratified 
by cluster group. Importantly, the additional significant principal components PC3 and PC4 
for days 0-3 were utilized in the k-means clustering, although they are not portrayed in the 
figure to simplify the visual interpretation to two dimensions. The two cluster groups 
primarily differ based on scores for PC1, wherein 100% of individuals in cluster 1 have a 
positive score for PC1, and a majority of individuals (61%) in cluster 2 have negative values 
for PC1.
The k-means clustering algorithm produced poorly separated clusters for days 4-5, where a 
predominant proportion (91%) of the study population was assigned to one nondescript 
cluster, with a small minority divided between two other clusters. As a result, further 
analyses were not performed with cluster groups for days 4-5.
3.3. Demographic and Clinical Variable Relationships to Day 0-3 Cluster Groups
The relationship between relevant demographic and clinical variables and cluster group are 
reported in Table 2. The average age of subjects in cluster 1 was significantly higher than in 
cluster 2 (46.09 vs. 31.75, p=<0.001). There was a lower proportion of men in cluster 1 
compared to cluster 2 (71.88% vs. 87.34%, p=0.05). The GCS, ISS, BMI, sepsis and 
pneumonia status for both cluster groups were not significantly different. Cluster 1 had a 
greater proportion of subdural hematomas (SDH) (87.50% vs.59.49%, p=0.004); however, 
cluster 1 had a lower proportion of diffuse axonal injuries (DAI) (9.38% vs. 43.04%, 
p=<0.001). The mechanism of injury significantly differed between the two clusters 
(p=<0.001), with a cluster 2 having greater frequencies of MVA or motorcycle accidents, 
and cluster 1 having more falls. The average length of acute hospital stay was significantly 
less for individuals in cluster 1 compared to cluster 2 (17.49 vs. 23.19 days, p=0.013).
A post-hoc analysis was conducted to examine differences in levels of CSF inflammatory 
markers, stratified above and below the 75th percentile of age, which was age 48 in our 
population. Further, as shown in Table 3, individuals above age 48 had significantly higher 
levels of IL-5, IL-6, IL-8, IL-10, sICAM-1, sVCAM-1, and sFAS (p<0.05 for all 
comparisons).
3.4. Demographic and Clinical Variable Relationships to GOS scores at 6 months
The relationship between relevant demographic and clinical variables and 6 month GOS are 
reported in Table 4. Age was significantly different by GOS categories at 6 months, with 
deceased individuals having a significantly higher average age at injury, while those with 
GOS scores of 2/3 and 4/5 had similar average ages (47.03 vs. 32.44 and 30.47). Presence of 
DAI was significantly different by outcome group (p=0.030), with the greatest proportion of 
DAI injuries among individuals with GOS scores of 4/5. The average acute length of stay 
among those that die was 15.70 days, while it was 25.56 days among those with GOS scores 
of 2/3 and 21.56 days for those with GOS scores of 4/5(p=0.003). No other variables tested 
were significantly different by GOS group. Demographic and clinical variables were also 
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examined for 12 month outcomes, and similar findings were seen to those reported for 6 
month GOS (data not shown). Therefore, based on the bivariate comparisons by cluster 
group and outcome, age, DAI, and length of acute hospital stay were controlled for in the 
multivariate model. Also, we added the best GCS score in the first 24 hours as a covariate in 
the model: 1) because of its marginal significance in bivariate analyses to cluster group and 
outcome; and 2) to control for a measure of injury severity in the multivariate model.
3.5. Relationship Between Cluster Group and 6 and 12 Month Outcomes
In bivariate analyses at 6 months, there was a significant association between cluster 
membership and GOS scores (p=<0.001). In cluster 1, 14 individuals (48.3%) were deceased 
at 6 months (GOS=1), 13 had GOS scores of 2/3 (38.2%), and 2 had GOS scores of 4/5 
(6.3%). In cluster 2, 15 individuals (22.7%) were deceased, and 21 (61.8%) and 30 (45.5%) 
of individuals had GOS scores of 2/3 and 4/5, respectively. There were also a significant 
association between cluster group and 12 month GOS scores (p=0.025) (data not shown).
All multivariate models examining the association between cluster group and outcome were 
adjusted for age, GCS, DAI, and acute hospital length of stay (see Table 5). The 
proportional odds assumption for the GOS score was checked before performing a 
multivariate ordinal logistic regression model. This test was significant (χ2=15.908, 
p=0.007), which indicates that proportionality was violated across levels of GOS; therefore, 
a multinomial logistic regression was conducted. This type of regression model does not 
assume proportionality among levels of the outcome (e.g. GOS=1 to GOS=2/3 to GOS=4/5). 
Therefore, each independent variable was modeled for its effects on GOS 1 vs. GOS 4/5, 
and GOS 2/3 vs. GOS 4/5.
Further, for 6 month GOS outcome among the study population, individuals in cluster 1 
compared to cluster 2, had a 10.9 times increased odds of GOS scores of 2/3 vs. 4/5 
(adjusted odds ratio (OR)=10.941, 95% CI (1.963, 60.978), p=0.006), after controlling for 
covariates. Individuals in cluster 1 vs. 2 did not differ in odds of GOS scores of 1 vs. 4/5 
(adjusted OR=4.142, 95% CI (0.663, 25.891), p=0.129), after controlling for covariates. Due 
to wide confidence intervals observed, post-hoc power analyses were conducted for each 
outcome comparison. Among GOS scores of 2/3 vs. 4/5, we calculated a power of 0.980 
using a Pearson chi-square test for two proportions, for an effect size of 10.94 between 
cluster groups, with a sample size of 34 and 32 for GOS 2/3 and GOS 4/5, respectively. 
Among GOS scores of 1 vs. 4/5, with a sample size of 29 for GOS 1 and 32 for GOS 4/5, 
and an effect size of 4.142, we calculated a modest power of 0.698.
Importantly, age was a significant predictor of GOS 1 vs. 4/5 (adjusted OR=1.061, 95% CI 
(1.011, 1.112), p=0.015). At 12 months, there were no significant multivariate relationships 
between cluster group and outcome (data not shown).
A post-hoc analysis was conducted examining the association between cluster group 
membership and DRS scores among survivors. As shown in Figure 4, there was a strong 
association between cluster group and DRS category (p=0.008), such that over half (56.9%) 
of subjects in cluster 2 had partial to no disability, while a majority of subjects (66.7%) in 
cluster 1 had moderate to severe disability. Also, the association between cluster group and 
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DRS at 12 months was not significant (data not shown).Of note, to protect against potential 
confounding, demographic and clinical covariates were checked for associations with DRS 
scores among survivors. We found that only DAI injury type was significantly different by 
DRS category, though its effect did not meaningfully change(i.e., >10% change in effect 
size) the association between cluster group and DRS at 6 months. Therefore, for simplicity 
of reporting this post-hoc analysis, the bivariate association is reported between cluster and 
DRS.
3.6. Relationship Between Cluster Group and TBI-relevant CSF and Serum Biomarkers
Average serum and CSF steroid hormone, BDNF, and S100b levels, stratified by cluster 
group are provided in Table 6. In CSF, day 0-3 average levels of cortisol, progesterone, E2, 
testosterone, BDNF, and S100b are higher in cluster 1 compared to cluster 2 (p<0.05 for all 
comparisons). In serum, average cortisol levels were higher in cluster 1 vs. cluster 2 
(p=<0.001). Average BDNF levels were lower in cluster 1 vs. cluster 2 (p=0.042).
Discussion
This study employs PCA and clustering methodology to characterize the neuro-
inflammatory response following TBI. The results offer a valuable addition to the field by 
providing a novel shift in approach in describing inflammation, from an absolute to a 
relative perspective. Immunology is a cybernetic physiological process where compensatory 
mechanisms (i.e. anti-inflammatory and pro-inflammatory markers) influence production 
and regulation of inflammatory agents (Hallenbeck, 1977). To date, the field of TBI has 
largely characterized inflammation using descriptive values of peaks or weekly means for a 
single marker at a time. Thus, there has been limited study into relative biomarker 
interrelationships in the clinical TBI setting, which has constrained the neurotrauma field to 
date in fully understanding the complexity of the inflammatory system and its role in injury 
and recovery. We contend that the overall approach to analyzing TBI biomarkers requires a 
holistic approach that considers multiple markers taken together. Specifically, our analyses 
highlight the importance of examining variations in an ensemble of inflammatory markers 
and considering inflammation data in the larger context of multiple markers representing 
other secondary injury pathways.
Age and Inflammation in the Context of TBI Recovery
The primary outcome of interest in this study was global outcome, which was assessed at 6 
and 12 months. Our results elucidate interesting and novel relationships between age, post-
traumatic inflammation, and recovery that are worthy of discussion. Namely, our data show 
that after multivariate adjustment in a multinomial model, age was the strongest predictor of 
risk for mortality compared to favorable outcomes at 6 months (GOS=4/5). However, 
inflammatory cluster membership was the most significant predictor of severe disability 
(GOS=2/3) compared to favorable outcomes (GOS=4/5).Similar results were seen using 
another disability scale, the DRS, where the majority of participants in cluster 1 had 
moderate or severe disability, and a majority of participants in cluster 2 had partial to no 
disability.
Kumar et al. Page 11













From these findings, it can be postulated that age and inflammation are closely related, 
though it appears their association to TBI recovery differs in keys aspects. With this in mind, 
we postulate three key mechanisms, conceptually outlined in Figure 5, that underlie an “age-
inflammation hypothesis” of TBI recovery. These include: 1) age effects independent of 
inflammation, 2) age-related inflammatory response, and 3) inflammation-related effects 
independent of age.
The first mechanism, age effects independent of inflammation, is well documented in TBI 
(Crownover et al., 2012; De Guise et al., 2015; Røe et al., 2013). The single greatest 
predictor of TBI-related deaths is older age, with nearly a 6% increase in risk of death for 
each year increase in age after injury (Harrison-Felix et al., 2004). The CDC estimates that 
individuals aged 65 and older at injury have over a 2.5 times increased risk of death 
compared to the next oldest age group, 45-64 year olds (CDC, 2001-2010). Importantly, 
individuals with TBI are twice as likely to die compared to individuals in the general 
population of similar age (Harrison-Felix et al., 2004). It is possible that some of this 
increased risk for mortality can be attributed to inflammatory-related pathways; however, it 
is also likely that other factors, unmeasured in this study, influence increased mortality 
burden, such as chronic comorbidities like hypertension, diabetes, and coronary artery 
disease(Centers for Disease Control and Prevention, 2010). Also, in our cohort older age 
was associated with specific mechanisms of injury (e.g. motor vehicle collisions and falls) 
that lead to particular brain injury pathology (e.g. DAI and SDH) that could have also 
influenced recovery course.
With respect to the second mechanism, the age-related inflammatory response, the literature 
suggests that age is associated with changes in microglial reactivity/functionality and a 
greater pro-inflammatory load (Lourbopoulos et al., 2015; Norden et al., 2014). Further, 
increases in pro-inflammatory load associated with aging may have an adverse impact on the 
secondary injury cascade, and the result could reduce antioxidant reserve and lead to 
mitochondrial dysfunction, which could accelerate neurodegeneration (Friedland-Leuner et 
al., 2013; Mocchegiani et al., 2014; Salminen and Paul, 2014; Xu et al., 2008). In our 
cohort, the PCA and cluster analysis were conducted with no a priori goal of observing 
associations between CSF inflammatory load and age; however, our data rendered a strong 
relationship between inflammatory cluster and older age. Specifically, in a post-hoc analysis 
conducted to examine differences in specific inflammatory markers associated with aging, 
we found that individuals above the 75th percentile for age in our cohort (age ≥48) had 
significantly higher levels of the exact set of seven inflammatory markers included in our 
PC1 that surpassed the |0.4| threshold using day 0-3 data. This suggests a unique 
inflammatory pattern that is characteristic among older adults with TBI that is distinct from 
the inflammatory response mounted by their younger counterparts with TBI.
The third mechanism refers to inflammation effects independent of age. This mechanism 
involves the role of inflammation in propagating the secondary injury cascade that is 
characteristic of TBI. This mechanism stresses the fundamental importance of how 
immunology interacts with and influences many other pathophysiological cascades and 
components characteristic of TBI. Our lab recently has explored how CNS inflammation 
interfaces with other pathways, specifically the neuroendocrine system. The work 
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demonstrated cortisol as a key mediator of inflammatory effects on outcome in TBI 
(Santarsieri et al., 2015). The data reduction capabilities of PCA provided an opportunity to 
characterize the complexities of the inflammatory response as an overall entity, explained by 
key principal components. Using data generated previously from our group, we identified 
key relationships that highlight the central role of acute post-traumatic inflammation in 
driving neurological and peripheral secondary injury responses across multiple pathways. 
Though only correlational, our results offer insights that may guide future research that 
explores in more depth how inflammation influences and interacts with neurotrophins and 
sex hormone physiology as well as, the relationships between inflammation and damage-
associated molecular pattern molecules, like S100b. We postulate that through its influence 
on the secondary injury cascade, increased inflammatory burden is associated with greater 
overall disability that is age-independent.
PCA as a Novel Approach to Characterize TBI Inflammation
In addition to unique age and inflammation related mechanisms on TBI recovery, the PCA 
approach to classification based on the inflammatory response provided several key novel 
insights, by identifying the relative importance of certain markers in explaining variability in 
post-traumatic inflammation. For example, IL-1β and TNFα are two of the most 
characterized and studied markers in the field of TBI. It is well-documented that these two 
markers are dramatically increased and are important mediators of the inflammatory 
response following TBI (Hayakata et al., 2004; Morganti-Kossman et al., 1997; Woodcock 
and Morganti-Kossmann, 2013). However, somewhat surprisingly, our data showed that 
IL-1β and TNFα provide a rather limited and similar contribution to variance in day 0-3 
inflammatory profiles compared to other PC1 and PC2 markers. This finding seems in 
contrast to the work by Helmy and colleagues that found that TNF and IL-1β were important 
contributors to their PC2 in the first 48 hours after injury among a small case series of 
individuals with TBI (Helmy et al., 2012). It could be interpreted that these markers are 
similarly elevated across the population in our study, and, although they are elevated 
considerably versus controls and related to recovery after severe TBI (Santarsieri et al., 
2015), they may provide little discriminative capacity in gauging degree of early inter-
individual variability after TBI.
From days 0-3 post-TBI, we derived four principal components that we used to form two 
independent clusters of CSF inflammatory profiles. The most dominant principal 
component, PC1, accounts for >31% of the variance in day 0-3 inflammatory profiles after 
TBI. The inflammatory markers with the strongest PC1 loading (>0.7) include the soluble 
cell-surface markers sICAM-1 and sFAS and the inflammatory cytokines IL-6 and IL-10. 
The absolute production of each of these markers in the context of TBI has been described 
previously (Ertel et al., 1997; Kirchhoff et al., 2006; Pleines et al., 1998; Santarsieri et al., 
2015; Shiozaki et al., 2005), though prior studies have not demonstrated the relatively 
similar importance of these markers in explaining variability of the inflammatory response 
after TBI. Because these markers collectively make similar contributions to variance, 
individuals with high PC1 scores are likely to have relatively high levels of sICAM-1, 
IL-10, IL-6 and sFAS. For PC2, for days 0-3, the markers with the greatest loading include: 
IL-7, IL-12, IL-4, and IL-6. Unlike PC1, however, not all of the loadings were positive. 
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Specifically, IL-6 had a loading of -0.4, which was approximately equal in magnitude and 
opposite in direction to IL-4 (loading=0.42), suggesting that higher PC2 scores are 
indicative of relatively higher IL-4 and lower IL-6. This could imply that compensatory 
mechanisms occur that involve IL-4, and perhaps also IL-7 or IL-12, which regulate the 
production of IL-6.
From days 4-5 after injury, PCA reveals that markers explaining the greatest variability are 
unique and largely different from those observed with the principal components generated 
for days 0-3. IL-1β and TNFα, which show relatively little variability early after injury, 
appear to have greater discriminative capacity days 4-5 after injury. We believe that this 
finding could indicate a transition for these markers later in the first week post-injury, from 
a more uniform role in initiating the inflammatory response early on, to markers that may be 
more dynamic and heterogeneous in their roles with perpetuating and regulating 
inflammation during the acute care phase post-TBI. A dynamic role for TNFα is well known 
from pre-clinical research where classic studies of TNFα knockout mice revealed a 
transition from early detrimental effects to delayed beneficial effects on behavioral 
outcomes over the initial 5 days post TBI (Scherbel et al., 1999). Conversely, IL-4 and 
IL-12 were two markers showing strong loading to day 0-3 PC2. Biologically, these markers 
have been implicated in the activation of microglia through T-cell mediation (Germann et 
al., 1993). However, by days 4-5, these markers appear to make little contribution to 
variation in inflammatory profiles. Thus, IL-4 and IL-12 cytokine activity may be critical for 
distinguishing patient status early on, whereas activity is likely similar across the population 
at later time points post-injury, suggesting either saturation or return to baseline state for 
these markers. Overall, day 4-5 data did not discriminate subjects into unique cluster 
groupings. Early microglial activation could vary and be critical to affecting outcome. 
Alternatively, it is possible that over time, considerable heterogeneity with treatment course, 
hospital complications, and surgical interventions confounds the clear discrimination of 
distinct groups.
Limitations
Despite the novelty and implications of this work, this study was not without limitations. 
First, the current study averaged cytokine levels across days 0-3, and there is without doubt 
some degree of inflammatory marker variability that occurs within this time frame. 
Explaining the most variance in the data does not automatically equate to providing the best 
prediction of outcome, and that in theory, many possible weighted combinations of subsets 
or markers could be tested for predictive power on a trial-and-error basis. However, the 
point of this study was to specifically evaluate the utility of the PC-based approach for 
clustering patients and predicting their outcomes, and thus the trial-and-error exploration of 
subsets of markers is outside the scope of this work. With that said, we have explored 
various temporal groupings for deriving meaningful clusters that discriminate outcome (data 
not shown). The day0-3 grouping performed best, and this analysis is what is reported for 
the manuscript. Future studies should be designed with a greater time resolution of blood 
draws (e.g., every six hours) to provide enough data to run separate daily PCA analyses over 
the first week post-injury. Importantly, the confidence intervals observed in this study were 
considerably wide. Nonetheless, post-hoc power analysis show sufficient power (∼98%) to 
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detect a difference in effect by cluster group in terms of capacity to discriminate between 
severe disability (GOS=2/3) versus moderate disability/good recovery (GOS=4/5), due to 
the magnitude of the effect size (OR=10.94). It is likely that this OR estimate is inflated, and 
we hypothesize that with a greater sample size, the effect size will still show a significant 
effect, but its magnitude will attenuate towards the null to some degree and the confidence 
interval will become narrower.
Also of note, the findings observed in this study were limited to 6 months post-injury and 
not apparent at 12 months. This apparent difference in significance is not entirely surprising, 
because as individuals with TBI become more removed from their point of injury, there is an 
increasing impact of psychosocial factors (e.g. environmental exposures, rehabilitative 
treatments, and social supports) on outcomes reported, particularly for global outcomes like 
GOS and DRS. This increasing contribution of later exposures, treatments and social 
support then naturally renders early biomarker (biological) characterizations associated with 
the initial phases of injury less informative. It is more likely that biological markers 
collected during later time points after the acute time frame will be better prognostic 
markers of long-term outcomes. In fact, based on our previous work, we know that 
inflammatory cytokine levels during the subacute period (2wk-3mo) after injury are 
predictive of global outcomes at both six and 12 months (Kumar et al., 2014).
Further, due to the strong association between aging and inflammation observed in this 
study, future work may benefit from prospectively collecting data on chronic diseases 
related to aging, such as hypertension, diabetes mellitus, and cardiovascular disease. 
Another limitation was the observational nature of this study makes it difficult to know 
whether biological relationships among cytokines, as well as between cytokines and other 
biomarkers, are due to direct effects or simply epiphenomena derived from other causal 
components of the secondary injury cascade. This clinical data can suggest productive 
directions for future experimental studies designed to elucidate biochemical interactions 
between markers.
Conclusions
Results from this study may have considerable implications to the field of TBI. Importantly, 
individuals with TBI have distinct patterns involving multiple CSF inflammatory markers 
that emerge and are detectable soon after injury. The data also show that unique groups of 
individuals can be distinguished acutely based on their CSF inflammatory profiles. This 
information provides some insight into which individuals are at an early risk for a 
prolonged, deleterious inflammatory response and, thus, may be good candidates for anti-
inflammatory treatment interventions. Markers identified as loading to PC1 appear to have 
the greatest relative importance in explaining variability observed with inflammatory 
cascades acutely after TBI. These candidate markers may be leveraged to generate reliable 
and informative screening tools for prognosis in TBI clinical care, particularly among 
survivors of TBI for discrimination of severity of disability. It is important to note that not 
all biomarkers with discriminative capacity for TBI outcomes may be effective 
discriminators of mortality. In contrast, other markers we have evaluated (e.g. serum 
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estradiol) are potent mortality predictors (Wagner et al., 2011) but have less predictive 
capacity among survivors (unpublished data).
As subsequent steps, we believe that PCA and clustering should be leveraged as data 
reduction methods that can be utilized in future adaptive clinical trials to identify patients at 
pre-specified time points who are most likely to benefit from an anti-inflammatory 
treatment. Additionally, older age and sex effects on variance in inflammatory profiles are 
substantial and require closer examination. Also, the association between cluster group and 
other biomarkers associated with the secondary injury response warrants further 
investigation in future studies. For example, experimental studies may benefit from 
examining how manipulation of one or more inflammatory markers affects other secondary 
injury responses, such as sex hormone physiology. Finally, future studies may build upon 
our work by using in silico mathematical modeling tools like differential equation models 
(Daun et al., 2008) to examine how manipulating one or more markers affects the intricacies 
of the inflammatory response and to suggest potential therapeutic targets to test in clinical 
trials.
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• We report principal components of acute CSF inflammation in severe TBI
• Using principal components, two unique clusters of TBI patients are identified
• Day 0-3 cluster group is a significant predictor of poor outcomes at 6 months
• Cluster groups discriminateCSF and serum hormone, BDNF, and s100b 
pathophysiology
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In this schematic, Var 1 corresponds to Hemoglobin-A1C and Var 2 corresponds to capillary 
blood glucose. PC1 is the first principal component derived from PCA that accounts for the 
greatest percentage of variance in the data. PC2 accounts for the remaining variance, not 
accounted by PC2. Abbreviations: Var=variable; PC=principal component
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Panel A: The loading of each CSF inflammatory biomarker to PC1 and PC2 for days 0-3 
post-injury. The markers significantly loading (≥0.4) to PC1 were: IL-5, IL-6, IL-8, and 
IL-10. The markers significantly loading to PC2 were: IL-4, IL-6, IL-7, IL-12.
Panel B: The loading of each CSF inflammatory biomarker to PC1 and PC2 for days 4-5 
post-injury. The markers significantly loading (≥0.4) to PC1 were: IL-1β, IL-6, IL-8, IL-10, 
TNFα, sVCAM-1, sICAM-1, sFAS. The markers significantly loading to PC2 were: IL-1β, 
TNFα, sVCAM-1, sICAM-1, and sFAS.
Abbreviations: CSF=cerebrospinal fluid; PC=principal component; IL=interleukin
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PC1 and PC2 scores are plotted for each individual for days 0-3 post-injury, stratified by 
cluster group 1 and 2. PC3 and PC4 scores were utilized in the assignment of cluster groups, 
though they are not portrayed in this graphic; Abbreviations: PC=principal component
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The Disability Rating Scale is divided into three categories: partial to no disability 
(DRS=0-3); 2) moderate or severe disability (DRS=4-14); 3) extreme severe disability, 
vegetative state or dead (DRS=15-29). Our data indicate a significant association between 
cluster group membership and DRS scores at 6 months (p=0.008). A majority of individuals 
in Cluster 1 had moderate or severe disability; however, a majority of individuals in Cluster 
2 had partial to no disability.
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We hypothesize that older age has the strongest influence on mortality after TBI through 
both inflammation independent and dependent effects; however, among survivors, an 
individual's CNS inflammatory load is a strong prognostic indicator of severity of disability 
post-injury
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Table 2
Clinical and Demographic Associations with Cluster Group
Cluster 1 (n=32) Cluster 2 (n=79) p-value
Age, mean (SE) 46.09 (3.27) 31.75 (1.55) <0.001*
Sex, Men (%) 23 (71.88) 69 (87.34) 0.050
GCS, Median (IQR) 6 (5-7) 7 (6-7.5) 0.166
ISS, Mean (SE) 32.81 (1.72) 34.38 (0.87) 0.235
BMI, Mean (SE) 26.14 (0.90) 26.92 (0.67) 0.815
Injury type from CT
 SDH 28 (87.50) 47 (59.49) 0.004*
 SAH 28 (87.50) 57 (72.15) 0.084
DAI 3 (9.38) 34 (43.04) <0.001*
 EDH 2 (6.25) 14 (17.72) 0.119
 Contusion 16 (50.00) 35 (44.30) 0.585
 IVH 11 (34.38) 21 (26.58) 0.411
 ICH 15 (46.88) 27 (34.18) 0.212
Mechanism of Injury, n (%)
 MVA 13 (40.63) 49 (62.82)
 Motorcycle 4 (12.50) 18 (23.08) 0.005*
 Fall 11 (34.38) 6 (7.69)
 Assault/fight 2 (6.25) 3 (3.85)
 Other 2 (6.25) 2 (2.56)
Length of Stay in Acute Care (days), Mean (SE) 17.49 (1.77) 23.19 (1.34) 0.013*
Length of Stay in Rehab (days), Mean (SE) 22.11 (5.55) 23.63 (3.73) 0.982
Sepsis, n (%) 3 (9.38) 2 (2.78) 0.712
Pneumonia, n (%) 20 (62.50) 45 (56.96) 0.592
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Table 3
CSF Inflammatory Cytokine Levels (pg/mL) in Age Above and the Below 75th Percentile 
Age
Age Quartile 1-3 Age Quartile 4† p-value
IL-1β (Mean, SE) 0.14 (0.04) 0.28 (0.12) 0.975
IL-4 (Mean, SE) 0.48 (0.06) 0.64 (0.12) 0.287
IL-5 (Mean, SE) 0.14 (0.02) 0.25 (0.05) 0.007*
IL-6 (Mean, SE) 732.33 (86.72) 1433.12 (180.73) <0.001
IL-7 (Mean, SE) 0.69 (0.04) 0.57 (0.08) 0.072
IL-8 (Mean, SE) 600.01 (94.08) 811.68 (170.95) 0.025*
IL-10 (Mean, SE) 22.72 (4.04) 47.98 (10.54) <0.001
IL-12 (Mean, SE) 0.10 (0.01) 0.10 (0.01) 0.922
TNFα 1.03 (0.14) 1.32 (0.45) 0.321
sICAM-1 36428.79 (12065.77) 86993.57 (32294.69) <0.001
sVCAM-1 4120.93 (376.01) 9975.85 (1457.28) <0.001
sFAS 203.20 (13.91) 432.42 (54.90) <0.001
†
Quartile 4 corresponds to age 48 or older
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Table 4
Clinical and Demographic Associations with 6 Month GOS Group
GOS=1 (n=29) GOS=2/3 (n=34) GOS=4/5 (n=32) p-value
Age, mean (SE) 47.03 (3.20) 32.44 (2.56) 30.47 (2.40) <0.001*
Sex, Men (%) 23 (79.31) 27 (79.41) 28 (87.50) 0.620
GCS, Median (IQR) 48 (36-60) 26 (20-44) 28 (21-35) 0.120
ISS, Mean (SE) 34.97 (1.64) 33.24 (1.52) 32.94 (1.35) 0.717
BMI, Mean (SE) 26.55 (0.97) 25.59 (1.01) 27.3 (1.03) 0.342
Injury type from CT, n (%)
 SDH 21 (72.41) 25 (78.13) 17 (54.84) 0.119
 SAH 25 (86.21) 23 (71.88) 22 (70.97) 0.303
DAI 5 (17.24) 9 (28.13) 15 (48.39) 0.030*
 EDH 5 (17.24) 3 (9.38) 4 (12.90) 0.660
 Contusion 18 (62.07) 14 (43.75) 13 (41.94) 0.228
 IVH 7 (24.14) 9 (28.13) 11 (35.48) 0.617
 ICH 10 (34.48) 11 (34.38) 0.873
Mechanism of Injury, n (%)
 MVA 10 (34.48) 17 (51.52) 20 (62.50)
 Motorcycle/Bicycle 6 (20.69) 7 (21.21) 7 (21.88)
 Fall 10 (34.48) 3 (9.09) 3 (9.38) 0.159
 Assault/fight 1 (3.45) 2 (6.06) 1 (3.13)
 Other 2 (6.90) 4 (12.12) 1 (14.29)
Length of Stay in Acute Care (days), Mean (SE) 15.70 (2.02) 25.56 (1.94) 21.56 (1.51) 0.003*
Length of Stay in Rehab (days), Mean (SE) n/a 25.14 (5.13) 21.14 (3.38) 0.982
Sepsis, n (%) 2 (7.69) 1 (3.03) 2 (6.90) 0.702
Pneumonia, n (%) 15 (51.72) 23 (67.65) 18 (56.25) 0.410
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Table 6
Day 0-3 CSF and Serum TBI-relevant Biomarkers by Cluster grou
Cluster 1 (n=32) Cluster 2 (n=79) p-value
CSF
 Cortisol (Mean, SE) 40.16 (4.04) 22.62 (2.19) <0.001*
 Progesterone (Mean, SE) 137.30 (25.24) 52.72 (4.83) <0.001*
 E2 (Mean, SE) 6.30 (0.98) 4.14 (0.41) 0.010*
 Testosterone (Mean, SE) 410.50 (103.28) 190.49 (31.20) 0.017*
 E2:Testosterone Ratio (Mean, SE) 0.07 (0.03) 0.06 (0.01) 0.391
 BDNF (Mean, SE) 0.246 (0.044) 0.209 (0.047) 0.050*
 S100b (Mean, SE) 4.83 (0.78) 2.73 (0.49) 0.001*
Serum
 Cortisol (Mean, SE) 290.43 (20.03) 196.31 (11.73) <0.001*
 Progesterone (Mean, SE) 3.23 (0.74) 2.44 (0.43) 0.074
 E2 (Mean, SE) 80.12 (12.87) 62.61 (4.27) 0.570
 Testosterone (Mean, SE) 3.83 (0.54) 4.00 (0.45) 0.920
 E2:Testosterone Ratio (Mean, SE) 31.94 (5.04) 31.77 (3.42) 0.969
 BDNF (Mean, SE) 131.59 (14.78) 174.52 (11.25) 0.042*
 S100b (Mean, SE) 12.16 (3.05) 16.15 (2.81) 0.347
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